Brief: Adagio Medical Holdings, Receives FDA Breakthrough Device Designation For The Vclastm Cryoablation System
17/04/2025 13:52
April 17 (Reuters) - Adagio Medical Holdings Inc ADGM.O: ADAGIO MEDICAL HOLDINGS, INC. RECEIVES FDA BREAKTHROUGH DEVICE DESIGNATION FOR THE VCLASTM CRYOABLATION SYSTEM Source text: ID:nBw5XftzMa Further company coverage: ADGM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagio Medical Holdings
See all newsBrief: Adagio Medical To Reduce Workforce By 25 Of 43 Employees Effective Sept 23, 2026 - SEC Filing
Brief: Adagio Medical Announces Strategic Review Process To Maximize Shareholder Value
Adagio Medical Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Adagio Medical Holdings Inc expected to post a loss of 28 cents a share - Earnings Preview
Brief: Adagio Medical Reports Second Quarter 2026 Results